AI English summary of an SEC filing — figures as filed

Gilead Sciences said on August 10, 2025 its Board of Directors appointed Erin Burkhart as Senior Vice President, Controllership and principal accounting officer, effective as of September 22, 2025.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Aug 14, 2025Period of report Aug 10, 2025Summary published (UTC) Oct 13, 2026

Key points

AI summary

Gilead Sciences said on August 10, 2025 its Board of Directors appointed Erin Burkhart as Senior Vice President, Controllership and principal accounting officer, effective as of September 22, 2025.
The company said Burkhart succeeds Diane E. Wilfong, who will step down as the Company's interim Controller and principal accounting officer, effective as of the Transition Date.
Gilead Sciences said Burkhart, age 46, has served as Group Vice President and Chief Accounting Officer of BioMarin Pharmaceutical Inc. since May 2022, and previously worked at Eli Lilly and Company from August 2014 to April 2022 in accounting and finance roles.
The company said Burkhart started her career in public accounting in 2001 with Arthur Andersen and Deloitte, is a licensed certified public accountant, and holds a B.S. in Accounting from Butler University.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Erin Burkhart Appointed, Effective September 22, 2025

Gilead Sciences said on August 10, 2025 its Board of Directors appointed Erin Burkhart as Senior Vice President, Controllership and principal accounting officer, effective as of September 22, 2025.

Source · Based on the filing body and exhibits

Diane E. Wilfong Steps Down as Interim Controller

The company said Burkhart succeeds Diane E. Wilfong, who will step down as the Company's interim Controller and principal accounting officer, effective as of the Transition Date.

Source · Based on the filing body and exhibits

Burkhart's Current and Prior Experience

Gilead Sciences said Burkhart, age 46, has served as Group Vice President and Chief Accounting Officer of BioMarin Pharmaceutical Inc. since May 2022, and previously worked at Eli Lilly and Company from August 2014 to April 2022 in accounting and finance roles.

Source · Based on the filing body and exhibits

Burkhart's Accounting Background and Education

The company said Burkhart started her career in public accounting in 2001 with Arthur Andersen and Deloitte, is a licensed certified public accountant, and holds a B.S. in Accounting from Butler University.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.